Application of economic analysis to diabetes and diabetes care

被引:56
作者
Zhang, P [1 ]
Engelgau, MM [1 ]
Norris, SL [1 ]
Gregg, EW [1 ]
Narayan, V [1 ]
机构
[1] CDCP, Div Diabet Translat, Atlanta, GA 30341 USA
关键词
D O I
10.7326/0003-4819-140-11-200406010-00039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Facing limited resources and increases in demand from competing programs, policymakers and health care providers seek guidance from economic studies on how to use health care resources wisely. Previous economic studies mainly focused on estimating the cost of diabetes and cost-effectiveness of different interventions. These studies found that diabetes is costly and that its cost will continue to increase; thus, more resources should be devoted to research aimed at finding effective means to prevent the disease and its complications. In addition, the cost-effectiveness of interventions varies greatly in terms of quality-adjusted life-years gained; therefore, efficient uses of resources should be an important consideration when interventions are prioritized. The need for economic studies will continue to grow because of increasing demand for limited resources from the growing number of interventions available. Future studies should be of better quality and broadened in areas of research.
引用
收藏
页码:972 / 977
页数:6
相关论文
共 27 条
[1]  
Bagust A, 2001, DIABETES, V50, pA2
[2]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[3]  
Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518
[4]   Guidelines for authors and peer reviewers of economic submissions to the BMJ [J].
Drummond, MF ;
Jefferson, TO .
BRITISH MEDICAL JOURNAL, 1996, 313 (7052) :275-283
[5]   Optimal allocation of resources across four interventions for type 2 diabetes [J].
Earnshaw, SR ;
Richter, A ;
Sorensen, SW ;
Hoerger, TJ ;
Hicks, KA ;
Engelgau, M ;
Thompson, T ;
Narayan, KMV ;
Williamson, DE ;
Gregg, E ;
Zhang, P .
MEDICAL DECISION MAKING, 2002, 22 (05) :S80-S91
[6]   Model of Complications of NIDDM .2. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia [J].
Eastman, RC ;
Javitt, JC ;
Herman, WH ;
Dasbach, EJ ;
CopleyMerriman, C ;
Maier, W ;
Dong, F ;
Manninen, D ;
Zbrozek, AS ;
Kotsanos, J ;
Garfield, SA ;
Harris, M .
DIABETES CARE, 1997, 20 (05) :735-744
[7]  
Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757
[8]   Cost-of-illness studies in diabetes mellitus [J].
Ettaro, L ;
Songer, TJ ;
Zhang, P ;
Engelgau, MM .
PHARMACOECONOMICS, 2004, 22 (03) :149-164
[10]   The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors [J].
Golan, L ;
Birkmeyer, JD ;
Welch, HG .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :660-+